Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, China.
Department of Urology & Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Institute of Urology, Guangzhou, Guangdong, China.
Biomed Res Int. 2020 Nov 23;2020:9321630. doi: 10.1155/2020/9321630. eCollection 2020.
DNA methyltransferase 3 alpha (DNMT3A) mutation was one of the most frequent genetic alterations in acute myeloid leukemia (AML), which was associated with poor prognosis and appeared to be a potential biomarker. Herein, we aimed to identify the key genes and pathways involved in adult AML with DNMT3A mutations and to find possible therapeutic targets for improving treatment.
The RNA sequencing datasets of 170 adult AML patients were obtained from The Cancer Genome Atlas (TCGA) database. EdgeR of the R platform was used to identify the differentially expressed genes (DEGs). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed by Metascape and DAVID. And protein-protein interaction (PPI) network and clustering modules were analyzed with the STRING database and Cytoscape software.
Mutated DNMT3A resulted in a shorter overall survival (OS) in AML patients and obviously associated with age, blast percentage in peripheral blood, and FLT3 mutation. A total of 283 DEGs were detected, of which 95 were upregulated and 188 were downregulated. GO term analysis showed that DEGs were significantly enriched in neutrophil degranulation, myeloid cell differentiation, stem cell proliferation, positive regulation of neurological system process, leukocyte migration, and tissue morphogenesis. KEGG pathway enrichment analysis indicated that the pathway of cancer, PI3K-Akt signaling pathway, and transcriptional misregulation in cancer may play a crucial role in DNMT3A mutation AML. Seven hub genes (BMP4, MPO, THBS1, APP, ELANE, HOXA7, and VWF) had a significant prognostic value.
Bioinformatics analysis in the present study provided novel targets for early diagnosis and new strategies for treatment for AML with DNMT3A mutation.
DNA 甲基转移酶 3α(DNMT3A)突变是急性髓系白血病(AML)中最常见的遗传改变之一,与预后不良相关,似乎是一个潜在的生物标志物。在此,我们旨在鉴定伴有 DNMT3A 突变的成人 AML 中涉及的关键基因和通路,并寻找可能改善治疗的潜在治疗靶点。
从癌症基因组图谱(TCGA)数据库中获取了 170 例成人 AML 患者的 RNA 测序数据集。R 平台中的 EdgeR 用于鉴定差异表达基因(DEGs)。使用 Metascape 和 DAVID 进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析。使用 STRING 数据库和 Cytoscape 软件分析蛋白质-蛋白质相互作用(PPI)网络和聚类模块。
突变的 DNMT3A 导致 AML 患者的总生存期(OS)更短,且与年龄、外周血中 blast 的百分比和 FLT3 突变明显相关。共检测到 283 个 DEGs,其中 95 个上调,188 个下调。GO 术语分析表明,DEGs 显著富集于中性粒细胞脱颗粒、髓样细胞分化、干细胞增殖、神经系统过程的正调控、白细胞迁移和组织形态发生。KEGG 通路富集分析表明,癌症、PI3K-Akt 信号通路和癌症转录失调等通路可能在 DNMT3A 突变 AML 中发挥关键作用。七个枢纽基因(BMP4、MPO、THBS1、APP、ELANE、HOXA7 和 VWF)具有显著的预后价值。
本研究的生物信息学分析为 DNMT3A 突变 AML 的早期诊断提供了新的靶点,并为治疗提供了新的策略。